At a glance
ClinicalIndex Comparison RecordPhase 1Not Yet Recruiting· 410 target
Drug / intervention
ICP-B794drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Multi-center, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ICP-B794 in Patients With Advanced Solid Tumors
In Brief
A Phase 1 clinical trial evaluating ICP-B794 for Advanced Solid Tumors. Not yet recruiting, targeting 410 participants across 1 site.
Detailed Summary
An Open-Label, Multi-center, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ICP-B794 in Patients with Advanced Solid Tumors
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Solid Tumors
CountriesChina
Collaborators--
Timeline
Phase 1Not Yet Recruiting
202620272028202920302031
Enrollment StartAug 2025
First PostedAug 2025
TodayJul 2026
Primary CompletionJun 2029
Study CompletionDec 2030
First PostedAug 22, 2025
Enrollment StartAug 1, 2025
Primary CompletionJun 1, 2029
Study CompletionDec 1, 2030
TodayJul 1, 2026
Enrollment to primary: 3.8 yearsPosted 10 months agoPrimary completion in 2.9 years
Interventions
ICP-B794drug
Intravenous administration once every 3 weeks